UK markets close in 6 hours 5 minutes
  • FTSE 100

    5,839.20
    -21.08 (-0.36%)
     
  • FTSE 250

    18,074.53
    -35.04 (-0.19%)
     
  • AIM

    983.67
    +3.22 (+0.33%)
     
  • GBP/EUR

    1.1055
    +0.0064 (+0.58%)
     
  • GBP/USD

    1.3058
    +0.0020 (+0.15%)
     
  • BTC-GBP

    10,015.33
    -3.10 (-0.03%)
     
  • CMC Crypto 200

    262.59
    +1.14 (+0.44%)
     
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • DOW

    28,335.57
    -28.13 (-0.10%)
     
  • CRUDE OIL

    38.98
    -0.87 (-2.18%)
     
  • GOLD FUTURES

    1,904.50
    -0.70 (-0.04%)
     
  • NIKKEI 225

    23,494.34
    -22.25 (-0.09%)
     
  • HANG SENG

    24,918.78
    +132.68 (+0.54%)
     
  • DAX

    12,361.00
    -284.75 (-2.25%)
     
  • CAC 40

    4,876.62
    -33.02 (-0.67%)
     

Novavax enters late-stage clinical trials

·1-min read
A vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19
A vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19

US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental Covid-19 vaccine.

The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.

"With a high level of SARS-CoV-2 transmission observed and expected to continue in the  UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373's efficacy," said Gregory Glenn, the company's president of research and development, using the technical name for the formulation.

It is the eleventh Covid-19 vaccine candidate to reach the Phase 3 stage globally.

The company has been awarded $1.6 billion by the US government to develop and fund the drug, which is administered by two intramuscular injections.

The Maryland-based company uses insect cells to grow synthesized pieces of the spike protein of the virus, which it hopes will evoke a robust human immune response.

It also uses an "adjuvant," a compound that boosts the production of neutralizing antibodies.

The company says the drug, which is a liquid formulation, can be stored at two degrees celsius to eight degrees celsius, refrigerator temperature.

In the spring, the company said it had proven the efficacy of a seasonal flu vaccine it had developed using the same technology.

ia/jh